PR022 is a new topical gel being studied for the treatment of atopic dermatitis. It is entering Phase 2 trials and it is being manufactured by Realm Therapeutics. Data is supposed to come out in the 3rd quarter of 2018.
PR022 consists of hypochlorous acid (HOCL). HOCL is an ideal wound care agent with powerful micobicidal, antibiofilm and wound healing potency. It is also found to be anti-inflammatory and anti-pruritic in atopic dermatitis in the mouse model. Inflammatory cytokines were reduced, notably IL-4 and IL-13, there was a significant reduction in itching.
The next phase of the study will be taking place in the United States and it consists of 120 patients with mild to moderate atopic dermatitis.
“Recently published peer-reviewed research has demonstrated PR022’s ability to prevent the development of atopic dermatitis-like lesions, reduce existing lesions and associated scratching, and reduce the inflammatory response,” Alex Martin, Realm CEO, said in a statement. “PR022 could offer an important alternative to patients suffering from atopic dermatitis and we are very excited about the potential of this new therapy.”
Over the past year we have seen new eczema products come to the market. For more mild to moderate eczema, Eucrisa has been released. For more moderate to severe eczema, Dupilumab has been a life saver for some patients.
The mainstay treatment of eczema has been topical steroids, but unfortunately there can be long term side effects with chronic usage such as thinning of the skin. Elidel and Protopic are also non steroidal creams available for patients. If PR022 has good data and is eventually FDA approved, it would add another option for atopic dermatitis sufferers. Current treatment regimens for eczema can be seen below.
If you suffer from eczema, see a dermatologist or allergy doctor who can help manage your symptoms. Please check back with us later for the development of PR022. As of now, there is no trade/brand name for it and no pricing is yet available.